



SCHEDULE

[^](#)
 AI2V 1: Waltham, MA - 8/1-4
 AI2V 2: Urbana, IL - 9/9-12
 Southfield, MI - 9/28
 Kansas City, MO - 9/29
 St. Paul, MN - 10/6
 Fargo-Moorehead, MN - 10/12
 Colorado, CO - 11/3
[v](#)

[About Us](#)
[Events](#)
[Resources](#)
[Archives](#)
[Purchase the I2V
Participant Guide](#)
[Read our Weblog](#)
[Contact I2V](#)

MADE POSSIBLE BY:



Ewing Marion
KAUFFMAN
 Foundation

ARCHIVES - 2005

AMERICAN CHEMICAL SOCIETY NATIONAL MEETING: Speaker Profiles

Simply click on any speaker to learn more.

[Peter Bonk](#)
[Lawrence A. Casper](#)
[Beverly Cormier](#)
[Wendy Elliott](#)
[Stephen F. Flaim](#)
[Judith Giordan](#)
[Rawle Hollingsworth](#)
[Paul S. Kedrosky](#)
[Ralph Kauten](#)
[Tim Rueth](#)
[Michael Strem](#)
[Joseph Steig](#)
[Ed Yokley](#)

Peter Bonk, Principal Scientist of Rhodes Technologies

Pete Bonk is Principal Scientist of Rhodes Technologies, a pharmaceutical manufacturing firm affiliated with Purdue Pharma. Prior to joining Rhodes Pete did process research and development at Abbott Laboratories for 9 years and spent 7 years in the Central Research Labs of Dow Chemical. Pete has a BS (Chem) degree from the University of Michigan and a Ph.D. from the University of Wisconsin. Pete has been involved with the ACS Division of Small Chemical Businesses for the past 10 years.

[Back to top](#)

Lawrence A. Casper, Assistant Dean, Research and Technology Transfer

Lawrence Casper was appointed assistant dean of research and technology transfer in 1990. His office is the primary contact point for business, industry and government to access technical capabilities in engineering. He is also involved in the UW Technology Enterprise Cooperative (UW-TEC) as Director of Entrepreneurial Projects. In 2004 Casper was made a "Wisconsin Idea Fellow" by the Board of Regents in recognition of his contributions to economic development in Wisconsin. Previously, Casper was an engineer for Honeywell Inc. Solid State Electronics Center, working on the engineering of materials and manufacturing processes for advanced microelectronic devices. He advanced to the rank of senior principal engineer and was elected by Honeywell management to the position of Engineering Fellow. Casper has been an active member of the American Chemical Society for many years, with several materials science symposia and books to his credit.

[Back to top](#)

Beverly Cormier, President, Bioscience Business Solution

Ms. Cormier has more than eighteen years experience spanning genomic, medical diagnostic, and medical device industries. She is currently President of BioScience Business Solutions, an executive consulting firm she founded in 2000. Clients include early and mid-stage private companies as well as large publicly traded corporations, to whom she provides a wide range of business commercialization services. In November 2001, Ms. Cormier took a sabbatical from BioScience Business Solutions to assume the role of Chief, Business Operations for Arcturus Applied Genomics, a clinical genomics company that develops diagnostic molecular signatures for disease. The remainder of her career has been spent in a variety of senior management roles with early stage and mid-stage companies, assisting two in moving from the private to the public sector. She graduated Cum Laude from the University of Cincinnati with a BS degree in Health Science Education and did her graduate work at Miami University in Health Care.

[Back to top](#)

Wendy Elliott, Grayhead Associates

In addition to her work with Grayhead Associates, Ms Elliott is the founder and Managing Director of Advanced Technology Management, Inc. She has more than 20 years of consulting, technology transfer, management, and product development and engineering experience. In her consulting practice Ms Elliott has helped clients: develop and implement new venture business plans; create joint new product development opportunities; design and implement "voice of the customer" studies; identify advanced manufacturing technologies and train high-potential managers in the management of R&D and engineering. Ms Elliott's prior experience includes Corporate Liaison Manager at MIT responsible for a multi-million dollar portfolio of European companies in the materials and manufacturing sector. She has conducted technology assessments; identified new technology and licensing opportunities and found investors for technology enterprises. Ms. Elliott career began as a Research Engineer where she gained experience in applied research and development including a background in polymer films, battery coating and magnetics. Ms Elliott received a BS in Chemical Engineering, and a MS Industrial Engineering (concentration Biomedical) from Northeastern University; an SM in the Management of Technology from the Sloan School of Management/School of Engineering at MIT. She was a Visiting Scholar at the 304 hospital in Beijing China and is presently a part time Visiting Scholar at MIT where her research focuses on the acquisition and commercialization of technology

[Back to top](#)

Stephen F. Flaim, F.A.C.C.

Dr. Flaim received his graduate degree in Human Physiology and Pharmacology from the University of California at Davis in 1975. He assumed a faculty position in Medicine and Physiology at the Pennsylvania State University College of Medicine at Hershey, PA. His early research focused on the mechanisms controlling the peripheral circulation in congestive heart failure and also contributed to the understanding of the cellular effects of the class of compounds now known as calcium channel blockers. In 1982, he assumed a lead research position in charge of Antianginal Drug Discovery at McNeil Pharmaceutical, a division of Johnson & Johnson. He subsequently took the position of Associate Director of Cardiovascular Pharmacology at the Squibb Institute for Medical Research where he was responsible for the Ion Channel Regulation Drug Discovery Program. In 1990, Dr. Flaim joined Alliance Pharmaceutical Corporation in San Diego where he was Vice President of Biological Sciences. At Alliance, Dr. Flaim was responsible for the preclinical development of perfluorocarbon-based products for use as temporary oxygen carriers during high blood-loss surgeries, liquid ventilation therapy for respiratory distress, and contrast enhancement during echocardiography. Dr. Flaim then took the position of Vice President of Biological Research & Development with Trega Biosciences, Inc. in San Diego where he was responsible for the drug discovery & development programs in pain management, inflammation, metabolic diseases and obesity. In 1999, Dr. Flaim became Senior Vice President of Research & Development at Galileo Pharmaceuticals, Inc. in Santa Clara, CA. In this role, he had overall responsibility for pharmaceutical drug discovery and development programs in myocardial ischemia, stroke, and inflammation focusing on chronic neuroinflammatory diseases. He also was responsible for the preclinical and clinical development aspects of the company's antiinflammatory bioactive nutraceutical programs. In 2003, Dr. Flaim established a private consulting firm supporting the biotechnology and pharmaceutical fields in the areas of preclinical and clinical research and development. Dr. Flaim is a Fellow of the American College of Cardiology, the American College of Clinical Pharmacology, and the Royal Society of Medicine. He is a member of the Editorial Board of the Journal of Pharmacology and Experimental Therapeutics, an advisor to the University of California School of Engineering Von Liebig Center for Entrepreneurism and Technology Development, a member of the San Diego Tech Coast Angels, and is active in numerous regional and national scientific organizations.

[Back to top](#)

Judith Giordan, Co-Founder and Principal, Aileron Partners

Judith C. Giordan has held executive and leadership positions in R&D and operations spanning more than a 20-year career. Currently, Giordan is a Director at Technology Option capital, LLC - an ICMB OceanTomo affiliated company, co-founder of Aileron Partners, a strategic and human capital services provider, as well as Distinguished Fellow of Entrepreneurial and Business Education, School of Polymers and High Performance Materials at The University of Southern Mississippi. Previous positions include vice president of International Flavors and Fragrances, Inc., global corporate director of research and development and vice president of worldwide research and development for Pepsi, vice president of research and development for Henkel Corporation and co-founder and managing partner of 1EXECStreet, a successful San Francisco-based executive search firm.

[Back to top](#)

Rawle Hollingsworth, Professor of Biochemistry, Molecular Biology, and Chemistry, Michigan State University

Mr. Hollingsworth holds a BS (1978) and a Ph.D. (1983) from The University of the West Indies. He was a Research Associate from 1983-87 at Michigan State University, as well as a Martin Luther King-Rosa Parks Fellow from 1987-88. Mr. Hollingsworth's current research interests include the application of spectroscopic methods and computational chemistry to the study of the structure and function of glycoconjugates and other macromolecules, and the chemical synthesis of saccharides. He started a business, Synthon Chiragenics, to develop and market his carbohydrate-based chiral technology for pharmaceuticals.

[Back to top](#)

Paul S. Kedrosky, Distinguished Fellow- von Liebig Center Jacobs School of Engineering,

UCSD

Dr. Paul Kedrosky is an award-winning academic, lecturer, and columnist. He has published more than three hundred articles in academic and non-academic publications on finance, entrepreneurship, strategy, and innovation. In addition, he has lectured and consulted to Fortune 1000 clients in Canada and the U.S. Dr. Kedrosky has appeared on many media outlets, including CNN, CNBC, PBS Newshour, ABC Nightline, and the New York Times. He writes a weekly column for the National Post in Canada, a monthly column for Canadian Business magazine, and weekly for RealMoney. His columns have also appeared in the Economist, the Wall Street Journal, the Brookings Institute, Forbes, and the Toronto Globe & Mail. Dr. Kedrosky has extensive industry experience, including having been a highly-ranked technology equity research analyst. He founded the technology equity research practice at HSBC James Capel (Canada), and transactions with which he was involved created in excess of a billion dollars in public market value. He continues to consult for various venture capital, money management, and hedge fund firms. He is currently a formal advisor to two ongoing technology-based companies, in addition to having founded various companies of his own. Dr. Kedrosky is currently a Distinguished Fellow at the William J. von Liebig Center for Entrepreneurism at the University of California, San Diego. In addition, Dr. Kedrosky is an adjunct professor in the management of technology at Simon Fraser University. He has also been a faculty member at the University of British Columbia, Faculty of Commerce. Dr. Kedrosky divides his time between La Jolla, California, and Vancouver, British Columbia.

[Back to top](#)

Ralph Kauten, President and CEO Quintessence Biosciences, Inc.

Mr. Kauten serves as President and CEO of Quintessence Biosciences, Inc. located in Madison, Wisconsin. Quintessence Biosciences, Inc. is a biopharmaceutical company focused on developing safe and effective cancer therapies based on the Company's innovative EVade™ ribonuclease technology. Mr. Kauten has served as co-founder and leader in a number of biotechnology companies including Promega Corporation, PanVera Corporation, and Mirus Corporation. Designated as an Entrepreneur of the Year by Ernst and Young, Mr. Kauten serves on numerous Boards of Directors and Advisory Boards for companies in the biotechnology industry and in other industries.

[Back to top](#)

Tim Rueth, San Diego Tech Coast Angels

Tim Rueth's technical foundation began with design, development and management experience in the areas of custom integrated circuit design and wireless systems. His most recent experience includes technology and business development, technology commercialization, both sides of fund-raising, due diligence, deal structure, and small company investment. He currently is a private investor and a member of the San Diego Tech Coast Angels, where he has served on its Board of Directors and the organization's screening committee, personally screening over 350 applications. In addition to his private investing activities, Mr. Rueth has been under contract with the University of California, San Diego, for over three years as a Technology and Business Advisor to commercialize technologies being developed within the Jacobs School of Engineering. Here, he has been instrumental in generating business strategies and industry interest in numerous University technologies as well as the formation of several start-up companies. Prior to his consulting/advising and private investing activities, Mr. Rueth was Vice President, IC Engineering, for start-up SCS Corporation. Prior to this, he was Vice President, Strategic Technology, for Qualcomm's ASIC Business Unit (now Qualcomm CDMA Technologies), and prior to this, he was a Senior Engineer at Hewlett Packard Company.

[Back to top](#)

Michael Strem, Division of Small Chemical Businesses, Strem Chemicals, Inc.

Academic Record: Brown University, A.B., 1958; University of Pittsburgh, MS., 1961; Ph.D., 1964. Professional Positions (for past ten years): Strem Chemicals, Inc., President, 1964 to date. Service in ACS National Offices: Director, Region I, 1998-00; Councilor, ex officio, 1998-00; Committee on Budget and Finance, 1998-03; Vice-Chair, 1999; Committee Associate, 1994-97; Committee on International Activities, 1998-03; Board Executive Committee, 1999; Committee on Public Affairs and Public Relations, 1998-99; Committee on Planning, ex officio, 1999-00; Committee on Committees, 1993-97; Committee on Professional Relations, 1989-92, Committee Associate, 1987-88; Committee on Technician Activities, Committee Associate, 1987; Advisory Board for Industry Relations, 1996-99; Canvassing Committee, ACS Award in Industrial Chemistry, 1989-91, Chair, 1990-91; National Chemistry Week Task Force, 1998-00; Task Force on Washington Information Technology, 1999; Task Force on Revision of Professional Employment Guidelines (PEG), 1991-92. Service in ACS Offices: Member ACS since 1960. Division of Small Chemical Businesses: Councilor, 1986-97; Chair, 1985, 1982-83; Chair-Elect, 1983-84, 1981-82; Program Committee Chair, 1988, 1983-84. Northeastern Section: Trustee 1997 to date; Chair, 1989; Chair-Elect, 1988; Board of Publications, Chair, 1994, 1991; Nominating Committee Chair, 1990-92. Northeast Regional Meeting: Exhibits Chair, 1993. Related Activities: Newburyport Business/Education Coalition, Inc., Board of Trustees, 1990 to date; Co-President, 2000-01, Newburyport Area Industrial Development Corporation, Board of Trustees 1990 to date; President 1994-96, Vice-President, 1992-94; Newburyport Emergency Planning Committee, 1994 to date; Member, Francis T. Bresnahan School Council, Newburyport, 1997-98; Institution for Savings, Newburyport, Trustee, 1993 to date; Corporator, Anna Jaques Hospital, Newburyport, 1992 to date; Research Biochemicals, Inc., Board of Directors, 1990-92; NRC Committee on Institutional Considerations in Reducing the Generation of Hazardous Industrial Wastes, 1983-84; Newburyport Chamber of Commerce, President, 1981; Catalysis Club of New England, Chair, 1976-78.

11/02mesresume

[Back to top](#)

Joseph Steig, Invention to Venture

Joseph Steig leads the Invention to Venture program for the NCIIA. He has a background in finance and strategic planning and has worked as a CFO with early stage companies in a diverse range of industries, including agriculture, environmental technologies, outdoor recreation products and software. Over the last fifteen years, in both a consulting and employee capacity, he has gained extensive operational experience helping move companies up the development curve, secure equity financing, and perform successfully against established milestones and objectives. For much of his career he has been closely involved in raising equity capital for companies and projects, particularly at the early stage with individual investors and venture capitalists, as well as at the mezzanine stage with larger investment banks and through corporate acquisitions. Additionally, Mr. Steig has extensive experience managing community economic development initiatives and in this work has gained a wide range of public process experience, working with universities, non-profits, government and business on developing shared development objectives. Through his consulting company, Innovation Path, he runs a New England-based angel investor group, River Valley Investors which has a primary focus on manufacturing and distribution companies.

[Back to top](#)

Ed Yokley, Principal On Target Management, Inc. Ed Yokley, Ph. D.- Principal --

Ed has a broad base of experience in marketing and leading operations for research teams, engineering teams and whole divisions and companies. His synthetic thinking ability, visualization processes and precise communication skills make him valuable in having unusual applied visions which elicit "Aha" understandings from team members and customers. Since 1986, Ed has combined his previous operations experiences and his training at MIT's Sloan School of Management in marketing to accomplish the following: development of global business strategies, identification of growth opportunities, production of new products, introduction of web based electronic commerce, direction of marketing and sales groups and raising profitability in organizations with sales ranging from \$60 million to \$300 million. Presently, he is Executive Vice President of SDI, one of On Target's clients. Ed has a BS degree in Chemistry from Xavier University, a Masters Degree from MIT's Sloan School of Management and a Ph.D. in Organic/Medicinal Chemistry from Indiana University.

[<<Back to workshop](#)

NCIIA • 100 Venture Way, Hadley MA 01035 • Tel: 1.413.587.2172 • Fax: 1.413.587.2175 • www.nciia.org •
info@invention2venture.org
© 2005 NCIIA All Rights Reserved.